Evidence map›Paper›PMID 29076108›Full record

ArticleAdvances in therapy2017

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.

Nicholas J Vogelzang, Sumanta K Pal, Sameer R Ghate, Elyse Swallow, Nanxin Li, Miranda Peeples, Miriam L Zichlin, Mark K Meiselbach, Jose Ricardo Perez, Neeraj Agarwal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. [Concepts in geriatric uro-oncology].Der Urologe. Ausg. A · 2019
    Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nicholas J VogelzangUS Oncology Research, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.
Sumanta K PalCity of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Sameer R GhateNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA. sameer.ghate@novartis.com.ORCID 0000-0001-8555-6363
Elyse SwallowAnalysis Group, Inc., Boston, MA, USA.
Nanxin LiAnalysis Group, Inc., Boston, MA, USA.
Miranda PeeplesAnalysis Group, Inc., Boston, MA, USA.
Miriam L ZichlinAnalysis Group, Inc., Boston, MA, USA.
Mark K MeiselbachAnalysis Group, Inc., Boston, MA, USA.
Jose Ricardo PerezNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Neeraj AgarwalHuntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionStudies indicate similar survival and toxicity between pazopanib and sunitinib, but few have examined real-world outcomes among elderly patients with advanced renal cell carcinoma (RCC). The purpose of this retrospective claims analysis was to assess real-world overall survival (OS), healthcare resource utilization (HRU), and healthcare costs (both all-cause and associated with RCC diagnosis) among elderly advanced RCC patients starting pazopanib or sunitinib treatment.

methodsAdvanced RCC patients aged 65 years or older who started first-line treatment with pazopanib or sunitinib (index drug; the initiation date was the index date) were identified from the 100% Medicare database plus Part D linkage (January 1, 2006 to December 31, 2014). Patients were stratified by index drug and matched 1:1 with use of propensity scores based on baseline characteristics. OS was assessed from the index date to death and compared by Kaplan-Meier analyses and univariable Cox models; patients were censored at the end of eligibility/data. Monthly HRU and costs from an intent-to-treat perspective were compared by Wilcoxon signed-rank tests.

resultsBaseline characteristics were balanced after matching (both N = 522). Treatment with pazopanib was associated with significantly longer median OS compared with treatment with sunitinib (18.2 months vs 14.6 months, respectively; log-rank p = 0.015). Pazopanib was associated with significantly lower monthly all-cause costs compared with sunitinib ($8845 vs $10,416, respectively), as well as lower inpatient costs associated with RCC diagnosis ($1542 vs $2522), fewer monthly inpatient admissions (0.179 vs 0.262), and shorter length of inpatient stay (1.375 days vs 1.883 days; all p ≤ 0.004).

conclusionsAmong elderly Medicare patients with advanced RCC, first-line pazopanib tretament was associated with significantly longer OS, as well as lower healthcare costs and HRU, compared with first-line sunitinib treatment.

Indexed as

AgedAntineoplastic AgentsCarcinoma, Renal CellDatabases, FactualFemaleHealth ExpendituresHumansIndazolesIndolesInsurance Claim ReviewKaplan-Meier EstimateKidney NeoplasmsMaleMedicareMiddle AgedPyrimidinesAntineoplastic AgentsIndazolesIndolespazopanibPyrimidinesPyrrolesSulfonamidesSunitinibAdvanced renal cell carcinomaClaims analysisElderlyHealthcare costsHealthcare resource utilizationMedicareOverall survivalPazopanibSunitinib

Identifiers

PMID29076108
PMCPMC5702370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.